ACA three-lens brief
Evidence-based stock research on ACA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 97% of its 52-week range — near the top of the band.
- Trading at 97% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
ACA closed at $145.25 (-0.10%) as of 2026-09-11. Market cap: $7.13B. P/E (trailing) 32.5. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.. Concerns: trading at 97% of its 52-week range — near the top of the band.. Last quarter: Revenue $658.70M, net income $328.50M, free cash flow $60.25M.
Why three lenses on ACA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACAacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ACA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACA brief"></iframe>